Short‐term hair regrowth ≥ 75% (between 12 and 26 weeks of · adults with alopecia areata
Summary of findings table ‐ Oral classical immunosuppressants… showed no clear difference in short‐term hair regrowth ≥ 75% (between 12 and 26 weeks of compared with oral classical immunosuppressants (azathioprine, methotrexate,… (low certainty).
1 finding from 1 review
Incidence of serious adverse events · adults with alopecia areata
1 finding from 1 review
Health‐related quality of life ‐ not reported · adults with alopecia areata
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Long‐term hair regrowth ≥ 75% (greater than 26 weeks of · adults with alopecia areata
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
HS‐LASI score · participants with hidradenitis suppurativa
1 finding from 1 review
Disease control (time when steroid could be discontinued) · bullous pemphigoid
1 finding from 1 review
Mortality at 1 year · bullous pemphigoid
It is very uncertain whether methylprednisolone plus azathioprine changes mortality at 1 year compared with methylprednisolone plus dapsone (very low certainty).
1 finding from 1 review
Quality of life ‐ not measured · bullous pemphigoid
The review found no eligible studies for this question.
1 finding from 1 review
Adverse events at 1 year · bullous pemphigoid
1 finding from 1 review
HRQOL ‐ not measured · Participants with rosacea
The review found no eligible studies for this question.
1 finding from 1 review
Participant‐assessed improvement in rosacea severity ‐ not measured · Participants with rosacea
The review found no eligible studies for this question.
1 finding from 1 review
Proportion of participants with adverse event · Participants with rosacea
Doxycycline 40 mg + metronidazole 1% gel may leads to lower proportion of participants with adverse event compared with doxycycline 100 mg + metronidazole 1% gel (low certainty).
1 finding from 1 review
Physician‐assessed improvement in rosacea severity · Participants with rosacea
1 finding from 1 review
Assessment of erythema or telangiectasia · Participants with rosacea
1 finding from 1 review
Lesion count · Participants with rosacea
1 finding from 1 review
Time needed until improvement of the skin lesions · Participants with rosacea
1 finding from 1 review
Duration of remission ‐ not measured · Participants with rosacea
The review found no eligible studies for this question.
1 finding from 1 review
Secondary: investigator‐rated reduction in severity ‐ Not measured · people (all patch‐tested) with hand eczema > 6 months that had cleared upon daily treatment for a maximum of 9 weeks with mometasone…
The review found no eligible studies for this question.
1 finding from 1 review
Primary: investigator‐rated good/excellent control of symptoms · people (all patch‐tested) with hand eczema > 6 months that had cleared upon daily treatment for a maximum of 9 weeks with mometasone…
Corticosteroid creams/ointments: mometasone furoate cream 3 times/week showed no clear difference in primary: investigator‐rated good/excellent control of symptoms compared with 2 times/week (low certainty).
1 finding from 1 review
Primary: participant‐rated good/excellent control of symptoms Not measured · people (all patch‐tested) with hand eczema > 6 months that had cleared upon daily treatment for a maximum of 9 weeks with mometasone…
The review found no eligible studies for this question.
1 finding from 1 review